Nigel Graizli
commented on
LIKE THIS. No way this is an original account but probably a spammer/stalker/spy
![I will be cleaning my followers list this long weekend. Those with no post are almost no visitors will be blocked. These are likely spies or stalkers.](https://ussnsimg.moomoo.com/sns_client_feed/73431062/20250217/9c43453bc008a55d9de50c207fa3e71e.jpg?area=100&is_public=true)
145
201
Nigel Graizli
liked and commented on
$Moleculin Biotech (MBRX.US)$
Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds
Thursday, 13th February at 1:05 pm
HOUSTON, Feb. 13, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of cer...
Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds
Thursday, 13th February at 1:05 pm
HOUSTON, Feb. 13, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of cer...
2
9
Nigel Graizli
liked
$Moleculin Biotech (MBRX.US)$
Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)
Thursday, 13th February at 9:25 am
Company remains on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) in the first quarter of 2025
HOUSTON, Feb. 13, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company w...
Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)
Thursday, 13th February at 9:25 am
Company remains on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) in the first quarter of 2025
HOUSTON, Feb. 13, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company w...
4
$Conduit Pharmaceuticals (CDT.US)$ can anyone let me know what the percent of shorts there are available?
Nigel Graizli
liked
Don't trust Chinese stocks. This is common sense.
2
2
Nigel Graizli
commented on
![Picture](https://sgsnsimg.moomoo.com/sns_client_feed/151667276/20250107/8fdfe229531a2c78df5681adfb5e3d03.jpg?area=102&is_public=true)
5
Nigel Graizli : just started following. please dont ban hammer me![sweat_smile 😅](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f605.png)